{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:28:55Z","timestamp":1790666935361,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91214103"],"award-info":[{"award-number":["91214103"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016032","name":"Nederlandse Cystic Fibrosis Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:38:45Z","timestamp":1683099525000},"page":"548-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes"],"prefix":"10.1016","volume":"22","author":[{"given":"E.","family":"de Poel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Spelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Hagemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Mourik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.F.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Brunsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.N.","family":"Ithakisiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kruisselbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Oppelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Berkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"de Winter de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heida-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Jans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Panhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-5767","authenticated-orcid":false,"given":"M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-7892","authenticated-orcid":false,"given":"J.","family":"Roukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dompeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.M.","family":"Weersink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8567-3252","authenticated-orcid":false,"given":"G.H.","family":"Koppelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-0760","authenticated-orcid":false,"given":"A.R.","family":"Blaazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Muijlwijk-Koezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jcf.2023.03.004_bib0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Disco."},{"issue":"3","key":"10.1016\/j.jcf.2023.03.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008341","article-title":"Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury","volume":"16","author":"Huang","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jcf.2023.03.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02529-2017","article-title":"Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function","volume":"52","author":"de Winter-de Groot","year":"2018","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.004_bib0006","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"issue":"344","key":"10.1016\/j.jcf.2023.03.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2023.03.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced Organoid Swelling is Associated with Long-term CF Disease Progression","author":"Muilwijk","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.03.004_bib0011","article-title":"High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing","author":"Spelier","year":"2022","journal-title":"Biorxiv"},{"issue":"14","key":"10.1016\/j.jcf.2023.03.004_bib0012","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: a review in COPD","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/hematology.2021000239","article-title":"Lifelong TKI therapy: how to manage cardiovascular and other risks","volume":"2021","author":"Mauro","year":"2021","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18101-8","article-title":"CFTR trafficking mutations disrupt co-translational protein folding by targeting biosynthetic intermediates","volume":"11","author":"Shishido","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2023.03.004_bib0015","article-title":"Assay validation in high throughput screening\u2013from concept to application","author":"Chai","year":"2015","journal-title":"Drug Discov Dev Mol Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.004_bib0016","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jcf.2023.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93029","article-title":"Chronic \u03b22AR stimulation limits CFTR activation in human airway epithelia","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15140-z","article-title":"2, 6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2023.03.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-1522","article-title":"Oral mucosal organoids as a potential platform for personalized cancer therapy","author":"Driehuis","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0021","first-page":"1","article-title":"High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids","volume":"10","author":"Folkesson","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms14262","article-title":"Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors","volume":"8","author":"Sch\u00fctte","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jcf.2023.03.004_bib0023","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.stemcr.2021.09.020","article-title":"A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients","volume":"16","author":"Jiang","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.004_bib0024","first-page":"724","article-title":"High-throughput surface liquid absorption and secretion assays to identify F508del CFTR correctors using patient primary airway epithelial cultures","volume":"24","author":"Berg","year":"2019","journal-title":"SLAS Discov Adv Life Sci R&D"},{"issue":"20","key":"10.1016\/j.jcf.2023.03.004_bib0025","doi-asserted-by":"crossref","first-page":"12657","DOI":"10.3390\/ijms232012657","article-title":"Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoids","volume":"23","author":"Rodenburg","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2023.03.004_bib0026","unstructured":"Vertex, Trikafta Prescribing Information (2021), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2023.03.004_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/jpet.102.047407","article-title":"Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H] piclamilast and [3H] rolipram","volume":"305","author":"Zhao","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.004_bib0028","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1021\/jm051273d","article-title":"Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase","volume":"49","author":"Huai","year":"2006","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.004_bib0029","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.jcf.2023.03.004_bib0030","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101320","article-title":"Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia","volume":"5","author":"Amatngalim","year":"2022","journal-title":"Life Sci Alliance"},{"issue":"10","key":"10.1016\/j.jcf.2023.03.004_bib0031","first-page":"1054","article-title":"Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-small cell lung cancer","volume":"10","author":"Yokota","year":"2021","journal-title":"Biology (Basel)"},{"issue":"4","key":"10.1016\/j.jcf.2023.03.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126444","article-title":"Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea","volume":"4","author":"Duan","year":"2019","journal-title":"JCI insight"},{"key":"10.1016\/j.jcf.2023.03.004_bib0033","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2018.11.012","article-title":"Lung function outcomes in the INPULSIS\u00ae trials of nintedanib in idiopathic pulmonary fibrosis","volume":"146","author":"Brown","year":"2019","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.03.004_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-06588-z","article-title":"Targeting the PI3K\/Akt\/mTOR signalling pathway in Cystic Fibrosis","volume":"7","author":"Reilly","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.004_bib0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jcf.2023.03.004_bib0036","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR","volume":"14","author":"Rowe","year":"2017","journal-title":"Ann Am Thorac So."},{"issue":"21","key":"10.1016\/j.jcf.2023.03.004_bib0037","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.03.004_bib0038","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.004_bib0039","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.03.004_bib0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"K","year":"2014","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:20Z","timestamp":1761601700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932300067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S156919932300067X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.004","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.02.506304","asserted-by":"object"}]},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}